

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5243172

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
YASUKO KINOSHITA	09/26/2018
YUMIKO KAWAI	09/26/2018
TOSHIAKI TSUNENARI	09/26/2018
TAKAHIRO ISHIGURO	10/09/2018
MIKA ENDO	09/26/2018
YUJI SANO	09/28/2018
RECEIVING PARTY DATA	
Name:	CHUGAI SEIYAKU KABUSHIKI KAISHA
Street Address:	5-1, UKIMA 5-CHOME, KITA-KU
City:	TOKYO
State/Country:	JAPAN
Postal Code:	115-8543
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16083975
CORRESPONDENCE DATA	
Fax Number:	(703)816-4100
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	7038164000
Email:	mgaszner@nixonvan.com, vbartels@nixonvan.com
Correspondent Name:	NIXON & VANDERHYE P.C.
Address Line 1:	901 N. GLEBE ROAD
Address Line 4:	ARLINGTON, VIRGINIA 22203
ATTORNEY DOCKET NUMBER:	6663.0103
NAME OF SUBMITTER:	MIKLOS GASZNER
SIGNATURE:	/Miklos Gaszner 61314/
DATE SIGNED:	11/19/2018
Total Attachments: 2	

source=6663_0103_Assignment#page1.tif

source=6663_0103_Assignment#page2.tif

ASSIGNMENT

In consideration of the sum of one dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Yasuko KINOSHITA, Yumiko KAWAI, Toshiaki TSUNENARI, Takahiro ISHIGURO, Mika ENDO, and Yuji SANO**, hereby sell and assign to Chugai Seiyaku Kabushiki Kaisha, a corporation formed under the laws of Japan, whose mailing address is 5-1, Ukima 5-chome, Kita-ku, Tokyo 115-8543 JAPAN (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as CELL INJURY INDUCING THERAPEUTIC DRUG FOR USE IN CANCER THERAPY for which application(s) for patent in the United States of America has a filing date or a 371(c) date of February 24, 2017 (also known as United States Application No. 16/083,975, which is the U.S. National Phase of International Application No. PCT/JP2017/007033, International Filing Date February 24, 2017), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

Michael G. Gorman
11.19.18

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient and further to perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 23117** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 23117** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

In witness whereof, executed by the undersigned inventors on the date opposite his/her name.

Date: <u>September 26, 2018</u>	Signature of Inventor: <u>Yasuko Kinoshita</u> Yasuko KINOSHITA
Date: <u>September 26, 2018</u>	Signature of Inventor: <u>Yumiko Kawai</u> Yumiko KAWAI
Date: <u>September 26, 2018</u>	Signature of Inventor: <u>Toshiaki Tsunenari</u> Toshiaki TSUNENARI
Date: <u>October 9, 2018</u>	Signature of Inventor: <u>Takahiro Ishiguro</u> Takahiro ISHIGURO
Date: <u>September 26, 2018</u>	Signature of Inventor: <u>Mika Endo</u> Mika ENDO
Date: <u>September 28, 2018</u>	Signature of Inventor: <u>Yuji Sano</u> Yuji SANO